The role of tumor necrosis factor-alpha in systemic lupus erythematosus
Open Access
- 1 January 2008
- journal article
- review article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 10 (1) , 202
- https://doi.org/10.1186/ar2341
Abstract
Murine models of systemic lupus erythematosus (SLE) have shown apparently contradictory evidence in that either (a) tumor necrosis factor (TNF) expression was low and TNF administration helpful or (b) TNF was high and TNF blockade of therapeutic benefit, depending on the mouse model investigated. In fact, TNF apparently has both effects, checking autoimmunity, at least to some degree, and fostering inflammation. TNF blockade regularly, but transiently, induces or increases autoantibodies to chromatin and to phospholipids. At the same time, open-label data suggest that TNF blockade suppresses inflammatory manifestations of SLE, and long-term benefit was seen in patients with lupus nephritis. A controlled clinical trial is under way.Keywords
This publication has 66 references indexed in Scilit:
- Efficacy and safety of Etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancyLupus, 2006
- Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritisClinical Rheumatology, 2006
- Case reports of etanercept in inflammatory dermatosesJournal of the American Academy of Dermatology, 2006
- Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritisNephrology Dialysis Transplantation, 2005
- Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFα antibodies (infliximab)European Journal of Gastroenterology & Hepatology, 2003
- Anti-tumour necrosis factor (TNF) α treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13Annals of the Rheumatic Diseases, 2002
- Serum IL-6, TNFα, p55 srTNFα, p75 srTNFα, srIL-2α Levels and Disease Acitivity in Systemic Lupus ErythematosusClinical Rheumatology, 1999
- Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis.Journal of Clinical Investigation, 1994
- Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosusArthritis & Rheumatism, 1993
- Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 miceClinical Immunology and Immunopathology, 1989